Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Francis deSouza, Guillermo Gualino, Robert Cantrell

Premium

Illumina President Francis deSouza has taken a seat on the firm's board of directors. The company added a spot on the board, boosting its number from nine to 10 seats, to accommodate deSouza. He will stand for re-election at the firm's 2014 shareholder meeting.

DeSouza joined Illumina as president in December. He previously was president of products and services at Symantec, which was acquired by Imlogic, a firm that deSouza founded and for which he served as CEO. He also worked at Microsoft, where he developed the company's real-time collaboration offerings.


Agilent Technologies has tapped Guillermo Gualino to be its VP and treasurer.

Gualino, who has been serving as assistant treasurer, replaces Robert Cantrell, who will shift to Keysight Technologies, a new electronic measurement company to be formed by Agilent's split into two publicly traded companies. Gualino will report to Agilent CFO Didier Hirsch.

Before he joined Agilent, Gualino was assistant treasurer at Flextronics International and he worked in finance at Ernst and Young, PricewaterhouseCoopers, and the Ventana Growth Fund.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.